Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Recruiting now · Not applicable

Conditions studied: Acute Lymphoblastic Leukemia

In brief

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Key facts

Study ID
NCT04179929
Run by
PETHEMA Foundation
People needed
300
Starts
2019-11-25
Expected to finish
2027-02-01
Last updated by the study team
2022-02-18

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.